Thousand Oaks biotech giant Amgen Inc. reported 4 percent revenue growth spurred by global product sales, but lowered its revenue guidance for the year in its third quarter financial results.  

Higher unit demand partially offset by lower selling prices is what drove revenue up to $6.7 billion. Double-digit volume growth was experienced by products such as osteoporosis treatments Prolia and Evenity, as well as cholesterol and cardiovascular disease treatment Repatha.  

Non-small cell lung cancer (NSCLC) drug Lumakras, which was approved earlier this year, accounted for $36 million in sales compared with the $9 million it brought in last quarter. Quarter three was the first full quarter of sales for the drug in the United States.   


Join our Membership to get the full story.

Are you a current Member? Sign In